Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study
Table 6
Analysis of associations between selected group variables and antibody half-lives for 3BNC117 and 10–1074 when administered in combination and when administered as single antibodies.